Artelo Biosciences, Inc. · NASDAQ:ARTL
Artelo Biosciences — Investor Presentation (November 2019)
27 slides from Artelo Biosciences's investor presentation, Nov 15, 2019
Slide 1: Artelo Biosciences – Investor Presentation November 2019
|OSCIENCES A clinical stage biopharmaceutical company developing and commercializing a portfolio of novel therapeutic candidates targeting the endocannabinoid system Nasdaq: ARTL November 2019
Slide 2: Forward Looking Statements
Forward Looking Statements ‘Statements in this presentation of Artelo Biosciences, Inc. (the “Company") that are not historical facts are “forward-looking statements" subject to risks/uncertainties. Such statements are based on current facts/analyses and other information that are based oon forecast
Slide 3: Artelo Biosciences, Inc.
Artelo Biosciences, Inc. Clinical stage biopharmaceutical company developing and commercializing a portfolio of novel therapeutic candidates targeting the Endocannabinoid System (ECS) - The ECS is a family of receptors and neurotransmitters that form a biochemical communication network throughout th
Slide 4: Pipeline
Pipeline Product Candidate Pre-clinical Phase 1 Phase 2 Market Size ART 27.13 Cancer Anorexia Cachexla Cannabinold Agonist ‘Syndrome: $28 Intammatory Bowel ART 12.11 IBD (Crohn’s & Colltls): BD Cocrystal Post-Traumatic Stress Disorder: $78. — Prostate Cancer: $88 ART 26.12 FABPS Inhibitor Breast Can
Slide 5: Patent Estate & Licenses
Patent Estate & Licenses Product Candidate Patent Status Lcense ART 27.13 cannabinoid Agonist ‘Two (2) issued patents (US & Intl) including composition of matter, term 11/3/25 Worldwide exclusive license ART 12.14 Pending composition of matter applications —_—_NIA (owned by Artelo) CBD Coerystal (US
Slide 6: ART 27.13 Cancer Anorexia Clinical Program
ART 27.13 Artelo CANCER ANOREXIA CLINICAL PROGRAM 4 BIOSCIENCES
Slide 7: Cancer Anorexia and Cachexia Syndrome (CACS) Remains a High Unmet Need
Cancer Anorexia and Cachexia Syndrome (CACS) Remains a High Unmet Need CACS therapy market currently exceeds $2 billion globally and could increase significantly with proprietary new market entries G10 04D We Cancer-related anorexia affects Although there are no FDA approved about 60% of advanced st
Slide 8: Link Between Cannabinoid Receptor Activation and Appetite is Well Established
Link Between Cannabinoid Receptor Activation and Appetite is Well Established Skelotal muscle Decreases glucose uptake ‘Adipose tissue Increases lipogenesis and increases adipocyte size Stimulates elease of leptin, an appetite stimulating hormone 6} Sends feeding signal to the brain Targeting recept
Slide 9: Cannabinoid-Based Drug is Unique Among Late Stage Agents Targeting CACS
Cannabinoid-Based Drug is Unique Among Late Stage Agents Targeting CACS ART27.13 is differentiated from other current clinical programs H 58 N oO aa + Peripherally restricted synthetic new chemical entity N + High-potency dual CB,/CB, cannabinoid agonist F + Established mechanism of action ' = Phage
Slide 10: Synthetic Cannabinoid Rationally Designed for an Attractive Safety Profile
Synthetic Cannabinoid Rationally Designed for an Attractive Safety Profile Peripheral acting ART27.13 avoids undesired cannabis “high” by targeting the body not the brain Acceptable side effect profile at the fended dose for the planned phase 2 study in cancer anorexia QO > Ed 4 8 8 ARTIT.A3 (250 v9
Slide 11: Correlation of Exposure to Weight Gain Observed in Phase 1 Study
Correlation of Exposure to Weight Gain Observed in Phase 1 Study Feeding and weight gain effect significantly different between ART27.13 and placebo weet ke Weight gain vs exposure on day 12 (MAD study, n=50) rd . = = oe Lupo ena, 2 ome ‘lip ascending dose (MAD) circa sud obem Scant aterent fort fat
Slide 12: ART27.13 Planned Phase 1b/2a Study
ART27.13 Planned Phase 1b/2a Study Duration: Artelo ‘A Phase ‘bi2a, Randomized, Placebo-Controlled Trial of the Synthet Patients with Gancer Anorexia and Weight Loss Phase 1b - Determine the most effective, safe dose (recommended Phase 2 dose, or RP2D) to be used in Stage 2 Phase 2a - Determine poin
Slide 13: ART 12.14 Proprietary CBD Cocrystal Program
ART 12.11 il PROPRIETARY CBD COCRY; L_ PROGRAM Artelo BIOSCIENCES
Slide 14: Creating a Better Cannabidiol (CBD)
Creating a Better Cannabidiol (CBD) @ > We are developing a more attractive CBD for pharmaceutical development a is What is good about CBD? What could be better? Our solution fe ‘Chemical has known medical applications GBD is in the public domain with CBD cocrystal 3 market exclusivity challenges 8
Slide 15: Cocrystals are Accepted in Pharmaceuticals and New to CBD
Cocrystals are Accepted in Pharmaceuticals and New to CBD @ > CBD cocrystal leverages an innovative, USPTO and FDA supported pharmaceutical strategy “ 2 CBD Cocrystalization @: pe Drug Comer CBD Cocrystal Innovator. FDA Indication Annual Approval Sales Blockbuster cocrystals Entresto® ‘Novartis 2015
Slide 16: Competitive Advantages of Next-Generation CBD Cocrystal
Competitive Advantages of Next-Generation CBD Cocrystal Potential next-generation benefits are derived from multiple proprietary features Proprietary Features Expected Benefits ¥ Unique now chemical entity > Proprietary to Artelo with worldwide market exclusivity V Addresses issues associated with p
Slide 17: Priority Indications for Development of Proprietary CBD Cocrystal
Priority Indications for Development of Proprietary CBD Cocrystal CBD activity in PTSD and IBD support ART12.11’s development strategy Post-Traumatic Stress Disorder Inflammatory Bowel Diseases (e) s H 4, 2 * Anxiety disorder caused by very stressful, frightening or + Illnesses characterized by chro
Slide 18: ART 26.12 FABP5 Inhibitor Program
ART 26.12 Artelo FABPS INHIBITOR PROGRAM BIOSCIENCES
Slide 19: Lipid Signaling Pathways are a Next-Generation Target for Cancer Therapeutics
ipid Signaling Pathways are a Next-Generation Target for Cancer Therapeutics FABP5 inhibitor was developed at Stony Brook University with multi-million dollar NIH funding + FABPS is an intra-cellular protein that serves as a carrier for certain lipids, including endocannabinoids and fatty acids * In
Slide 20: FABP5 is a Validated Target in Breast, Prostate, and Cervical Cancer
FABPS5 is a Validated Target in Breast, Prostate, and Cervical Cancer C ) fesse itinsng ott cies a | ard essen i tar ra HT Is upregulated in triple negative breast. B. 2 cancer (C), and is associated with poor» “™* é prognosis (0). Bam x A_sco0 2 os =. P0004 z E1600 wr Boe & E 1600 Lp 2 3 teoo | -o>
Slide 21: FABP5 Inhibitor Decreases Tumor Growth in Prostate Cancer Model
FABPS Inhibitor Decreases Tumor Growth in Prostate Cancer Model SBFI26 = ART26.12 Ghrelin Artelo —*—Control(PBS) @=SBF126(from day 7) —t—SBFI26(from day 1) 6 9 13° (17) 21024 Days 28 31 a 2) > 3 a
Slide 22: Company
COMPANY Artelo BIOSCIENCES
Slide 23: Proven Leadership
Proven Leadership MANAGEMENT TEAM GREGORY GORGAS President & CEO, Director Biogenidee, Chiron, Cet, Upjohn Proven global Bophame success ‘nt four ftin-sics launches STEVEN D. REICH, MD Cher Meateal omcer Peer, igen, Bogen, PAREXEL Demonstrated cinea! rack record Pharmaceutical indutey JASON BAYBUTT
Slide 24: Company Capitalization
Company Capitalization (Nasdaq: ARTL) Market Cap USD $7.39M. Shares Outstanding 3,415,016 Warrants 2,143,875 Options 231,500 Fully Diluted 5,790,376 Data fam October 16, 2019 Artelo yf Nasdaq ‘Series A warrant strike price ~ $8.00 (# 24,042) Series B warrant strike price - $12.00 # 163,620), Series
Slide 25: Accomplished and Anticipated Milestones
Accomplished and Anticipated Milestones 4H 2019 Raised $1.6M in private placements ¥ Public offering $8M (net $7.3M) ¥ Nasdaq listing 2H 2019 art27.13 Licensing payment fully paid ¥ ART26.12 Milestone one payment made for accomplishing lead optimization ¥ ART26.12 Publication of non-clinical researc
Slide 26: Company Summary
Company Summary @ © NOVEL DRUG ROBUST NEAR-TERM | BILLION DOLLAR PROVEN PIPELINE PATENT ESTATE | MILESTONES MARKETS LEADERSHIP Developing federally Comprehensive issued (4) | Cinical milestone TTargetindications forthe Experienced team of regulated therapeutics and pending (4) patents | readout expe
Slide 27: Artelo Biosciences
Artelo BIOSCIENCES For more information: www.artelobio.com
Artelo Biosciences — Investor Presentation (November 2019) on 6ix